Cost-effectiveness of carfilzomib plus dexamethasone compared with bortezomib plus dexamethasone for patients with relapsed or refractory multiple myeloma in the United States

References

• SEER. Surveillance, Epidemiology, and End Results Program. Myeloma: Stat Fact Sheets; 2017. Accessed Oct 4. http://seer.cancer.gov/statfacts/html/mulmy.html
   Google Scholar
• Chauhan D, Li G, Podar K, et al. Targeting mitochondria to overcome conventional and bortezomib/proteasome inhibitor PS-341 resistance in multiple myeloma (MM) cells. Blood. 2004;104(8):2458–2466.
   PubMed Web of Science ®Google Scholar
• Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med. 2005;352(24):2487–2498.
   PubMed Web of Science ®Google Scholar
• Richardson PG, Delforge M, Beksac M, et al. Management of treatment-emergent peripheral neuropathy in multiple myeloma. Leukemia. 2012;26(4):595–608.
   PubMed Web of Science ®Google Scholar
• Walker M, Cong Z, Knopf K, et al. Real world impact of treatment-induced peripheral neuropathy (TIPN) on patient reported outcomes (PROs) in patients with multiple myeloma (MM) in the United States. J Clin Oncol. 2015;33(suppl; abstr e19531). DOI: 10.1200/jco.2015.33.15_suppl.e19531
   Google Scholar
• Panjabi S, Song X, Wilson K, et al. Costs associated with treatment induced peripheral neuropathy in patients with multiple myeloma by lines of therapy. Abstract presented at: 58th Annual Meeting & Exposition. San Diego, CA. December 3-6, 2016.).
   Google Scholar
• Demo SD, Kirk CJ, Aujay MA, et al. Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome. Cancer Res. 2007;67(13):6383–6391.
   PubMed Web of Science ®Google Scholar
• Kuhn DJ, Chen Q, Voorhees PM, et al. Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma. Blood. 2007;110(9):3281–3290.
   PubMed Web of Science ®Google Scholar
• Huber EM, Heinemeyer W, Groll M. Bortezomib-resistant mutant proteasomes: structural and biochemical evaluation with carfilzomib and ONX 0914. Structure. 2015;23(2):407–417.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Moreau P, Palumbo A, et al. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol. 2016;17(1):27–38.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Goldschmidt H, Niesvizky R, et al. Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial. Lancet Oncol. 2017;18(10):1327–1337.
   PubMed Web of Science ®Google Scholar
• Amgen Press Release. Second phase 3 study shows KYPROLIS® (Carfilzomib) regimen significantly improves overall survival in patients with relapsed multiple myeloma. [cited 2017 Oct 11]. Available from: http://wwwext.amgen.com/media/news-releases/2017/07/second-phase-3-study-shows-kyprolis-carfilzomib-regimen-significantly-improves-overall-survival-in-patients-with-relapsed-multiple-myeloma/.
   Google Scholar
• Ludwig H, Moreau P, Dimopoulos M et al. Health related quality of life results from the open-label, randomized, phase iii endeavor trial evaluating carfilzomib and dexamethasone versus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma. Abstract presented at: 58th Annual Meeting & Exposition. San Diego, CA. 2016 Dec 3-6. (2016).
   Google Scholar
• NCCN. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology. Multiple Myeloma. 2017;v2.2018. Available from: https://www.nccn.org/professionals/physician_gls/pdf/myeloma.pdf
   Google Scholar
• Human Mortality Database. University of California, Berkeley (USA), and Max Planck Institute for Demographic Research (Germany). [ cited 27 April 2017]. Available at: www.mortality.org or www.humanmortality.de.
   Google Scholar
• Latimer N NICE DSU Technical Support Document 14: survival analysis for economic evaluations alongside clinical trials - extrapolation with patient-level data. June 2011 .[updated 2013 Mar; cited 2017 Jan 30]. Available from: http://www.nicedsu.org.uk/Survival-analysis-TSD(2892878).htm.
   Google Scholar
• San-Miguel J, Hungria V, Yoon S, et al. Final analysis of overall survival from the phase 3 panorama 1 trial of panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma. Blood. 2015;126:3026.
   Web of Science ®Google Scholar
• Orlowski RZ, Nagler A, Sonneveld P, et al. Final overall survival results of a randomized trial comparing bortezomib plus pegylated liposomal doxorubicin with bortezomib alone in patients with relapsed or refractory multiple myeloma. Cancer. 2016;122(13):2050–2056.
   PubMed Web of Science ®Google Scholar
• Jackson C, Stevens J, Ren S, et al. Extrapolating survival from randomized trials using external data: a review of methods. Med Decis Making. 2017;37(4):377–390.
   PubMed Web of Science ®Google Scholar
• Jakubowiak AJ, Campioni M, Benedict A, et al. Cost-effectiveness of adding carfilzomib to lenalidomide and dexamethasone in relapsed multiple myeloma from a US perspective. J Med Econ. 2016;19(11):1061–1074.
   PubMed Web of Science ®Google Scholar
• Van Agthoven M, Segeren CM, Buijt I, et al. A cost-utility analysis comparing intensive chemotherapy alone to intensive chemotherapy followed by myeloablative chemotherapy with autologous stem-cell rescue in newly diagnosed patients with stage II/III multiple myeloma; a prospective randomised phase III study. Eur J Cancer. 2004;40(8):1159–1169.
   PubMed Web of Science ®Google Scholar
• Truven Health Analytics. RED BOOK. Ann Arbor, MI: Truven Health Analytics; 2016. Ann Arbor, MI; 2013. [cited 2017 Mar 31]. Available from: http://sites.truvenhealth.com/redbook/index.html.
   Google Scholar
• HCUPnet National Inpatient Sample (NIS), Agency for Healthcare Research and Quality (AHRQ). National statistics by principal diagnosis code. Rockville, MD: Agency for Healthcare Research and Quality; 2013. [cited 2016 Mar 29]. Available from: http://hcupnet.ahrq.gov/
   Google Scholar
• Amgen Inc. Data on File. Retrospective study of healthcare utilization and costs in patients with multiple myeloma using Truven MarketScan data through. Thousand Oaks, CA, USA: Amgen Inc; 2014 Dec.
   Google Scholar
• National Institute for Health and Care Excellence (NICE) technology appraisal guidance (TA171). Lenalidomide for the treatment of multiple myeloma in people who have received at least one prior therapy. England, UK: NICE; 2009. [updated 2014 Apr; cited 2016 Sep 21]. https://www.nice.org.uk/guidance/ta171
   Google Scholar
• Novartis. Panobinostat for treating multiple myeloma in people who have received at least one prior therapy. In: ID663 Single technology appraisal (STA) manufacturer’s submission. Basel, Switzerland: Novartis; 2015.[cited 2016 Sept 21]. Available from: http://www.nice.org.uk/guidance/indevelopment/gid-tag477/documents
   Google Scholar
• pan-Canadian Oncology Drug Review (pCODR). pan-Canadian Oncology Drug Review Final Economic Guidance Report Lenalidomide (Revlimid) for multiple myeloma 2013; cited 2016 Sep 21]. Available from: https://www.cadth.ca/sites/default/files/pcodr/pcodr-revlimid-mm-fn-egr.pdf.
   Google Scholar
• pan-Canadian Oncology Drug Review (pCODR). pan-Canadian Oncology Drug Review Final Economic Guidance Report Pomalidomide (Pomalyst) for multiple myeloma 2014; [cited 2016 Sept 21]. Available from: https://www.cadth.ca/sites/default/files/pcodr/pcodr-pomalyst-mm-fn-egr.pdf.
   Google Scholar
• Scottish Medicines Consortium (SMC). SMC Advice: lenalidomide (Revlimid). 2015; [cited 2016 Sep 21]. Available from: https://www.scottishmedicines.org.uk/SMC_Advice/Advice/1096_15_lenalidomide_Revlimid/lenalidomide_Revlimid.
   Google Scholar
• National Institute for Health and Care Excellence (NICE) technology appraisal guidance [TA 380]. Panobinostat for treating multiple myeloma after at least 2 previous treatments. England, UK: NICE; 2016. [cited 2016 Sep 21]. Available from: https://www.nice.org.uk/guidance/ta380
   Google Scholar
• Proskorovs.ky I, Lewis P, Williams CD, et al. Mapping EORTC QLQ-C30 and QLQ-MY20 to EQ-5D in patients with multiple myeloma. Health Qual Life Outcomes. 2014;12:35.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence (NICE) technology appraisal guidance [TA338]. Pomalidomide for relapsed and refractory multiple myeloma previously treated with lenalidomide and bortezomib. England, UK: NICE; 2015. [cited 2017 Jan 30]. Available from: https://www.nice.org.uk/guidance/ta338
   Google Scholar
• Hillner BE, Smith TJ. Efficacy does not necessarily translate to cost effectiveness: a case study in the challenges associated with 21st-century cancer drug pricing. J Clin Oncol. 2009;27(13):2111–2113.
   PubMed Web of Science ®Google Scholar
• Braithwaite RS, Meltzer DO, King JT, et al. What does the value of modern medicine say about the $50,000 per quality-adjusted life-year decision rule? Med Care. 2008;46(4):349–356.
   PubMed Web of Science ®Google Scholar
• Ubel PA, Berry SR, Nadler E, et al. In a survey, marked inconsistency in how oncologists judged value of high-cost cancer drugs in relation to gains in survival. Health Aff (Millwood). 2012;31(4):709–717.
   PubMed Web of Science ®Google Scholar
• Nadler E, Eckert B, Neumann PJ. Do oncologists believe new cancer drugs offer good value? Oncologist. 2006;11(2):90–95.
   PubMed Web of Science ®Google Scholar
• Aldy J, Viscusi W. Adjusting the value of a statistical life for age and cohort effects. Rev Econ Stat. 2008;90(573–581).
   PubMedGoogle Scholar
• Amgen Press Release. Long-term analysis of phase 3 head-to-head study confirms Kyprolis® (carfilzomib) regimen extends overall survival in patients with relapsed multiple myeloma. [ cited 2017 October 4]. Available from: http://wwwext.amgen.com/media/news-releases/2017/08/longterm-analysis-of-phase-3-headtohead-study-confirms-kyprolis-carfilzomib-regimen-extends-overall-survival-in-patients-with-relapsed-multiple-myeloma/.
   Google Scholar
• Stewart AK, Rajkumar SV, Dimopoulos MA, et al. Carflizomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med. 2015;372:142–152.
   PubMed Web of Science ®Google Scholar
• Roy A, Kish JK, Bloudek L, et al. Estimating the costs of therapy in patients with relapsed and/or refractory multiple myeloma: a model framework. Am Health Drug Benefits. 2015;8(4):204–215.
   PubMed Web of Science ®Google Scholar
• Chng WJ, Goldschmidt H, Dimopoulos MA, et al. Carfilzomib-dexamethasone vs. bortezomib-dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR. Leukemia. 2017;31(6):1368–1374.
   PubMed Web of Science ®Google Scholar
• Fonseca R, Abouzaid S, Bonafede M, et al. Trends in overall survival and costs of multiple myeloma, 2000-2014. Leukemia. 2017;31(9):1915–1921.
   PubMed Web of Science ®Google Scholar
• Go RS, Bartley AC, Crowson CS, et al. Association between treatment facility volume and mortality of patients with multiple myeloma. J Clin Oncol. 2017;35(6):598–604.
   PubMed Web of Science ®Google Scholar
• Hostenkamp G, Lichtenberg FR. The impact of recent chemotherapy innovation on the longevity of myeloma patients: US and international evidence. Soc Sci Med. 2015;130:162–171.
   PubMed Web of Science ®Google Scholar